Allogene publishes on positive response in Phase 1 CART for lymphoma trial

 

• Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, Respectively
• Durability of Response: Among Patients Who Achieved CR, Median Duration of Response (DOR) of 23.1 Months and Median Overall Survival (OS) Not Reached
• Manageable Safety Profile Consistent with Approved Autologous CD19 CAR T: No Graft-versus-Host Disease (GvHD), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), or High-Grade Cytokine Release Syndrome (CRS)
• On-Demand Treatment: Median Time to Treatment Two Days from Enrollment
• Foundation for Cema-Cel in ALPHA3 Trial in First Line (1L) Consolidation: Achieved 100% CR in Patients with Low Disease Burden

https://www.globenewswire.com/news-release/2025/02/13/3026325/0/en/Allogene-Therapeutics-Announces-Publication-of-Durable-Response-Data-from-Phase-1-ALPHA-ALPHA2-Trials-of-the-Allogeneic-CAR-T-Cemacabtagene-Ansegedleucel-ALLO-501-in-Relapsed-Refra.html